BioSpace News Archive

Reviva Pharmaceuticals Holdings, Inc. is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows.

GE HealthCare announced that its previously announced spin-off from GE is complete and GE HealthCare will begin trading as an independent company on the Nasdaq exchange under the ticker symbol “GEHC”.

Editas Medicine, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.

G1 Therapeutics, Inc. today provided an initial update on PRESERVE 3, an ongoing Phase 2, randomized, open-label study of first-line platinum-based chemotherapy and maintenance therapy with the immune checkpoint inhibitor, avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC).

Caris Life Sciences announced today that the company will present at the 41st Annual J.P. Morgan Healthcare Conference, which is being held January 9-12, 2023.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 1,000 shares of KalVista common stock on January 3, 2023 as inducement material to such employee entering into employment with KalVista.

Indigo Diabetes N.V., a pioneering developer of Continuous Metabolite Monitoring devices utilising proprietary nanophotonics technology, provides an update on recent and ongoing business activities.

Immunocore Holdings Plc today announced that management will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference.

Orano Med announced that the first patient has been dosed in a Phase 1 trial of the alpha radioligand therapy with lead-212, 212Pb-GRPR, in patients with advanced solid tumors that express gastrin-releasing peptide receptor.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells.